# Prestige Consumer Healthcare Inc.: overview

PBH · NYSE · CIK 1295947 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/pbh.md) · [Financials](/companies/pbh/financials.md) · [Filings](/companies/pbh/filings.md) · [Insiders](/companies/pbh/insiders.md)

Latest reported revenue: [$265.7m](/filings/0001295947-26-000042.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001295947-26-000042).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [284](/filings/0001295947-25-000039.md) | [290](/filings/0001295947-26-000008.md) | [297 d](/filings/0001295947-26-000016.md) | [250](/filings/0001295947-26-000042.md) | [274](/filings/0001295947-25-000039.md) | [283](/filings/0001295947-26-000008.md) | [282 d](/filings/0001295947-26-000016.md) | [266](/filings/0001295947-26-000042.md) |
| Gross margin | % | [55.5%](/filings/0001295947-25-000039.md) | [55.5%](/filings/0001295947-26-000008.md) | [57.3% d](/filings/0001295947-26-000016.md) | [56.2%](/filings/0001295947-26-000042.md) | [55.3%](/filings/0001295947-25-000039.md) | [55.5%](/filings/0001295947-26-000008.md) | [51.9% d](/filings/0001295947-26-000016.md) | [51.3%](/filings/0001295947-26-000042.md) |
| Operating margin | % | [29.7%](/filings/0001295947-25-000039.md) | [31.7%](/filings/0001295947-26-000008.md) | [29.8% d](/filings/0001295947-26-000016.md) | [28.8%](/filings/0001295947-26-000042.md) | [29.1%](/filings/0001295947-25-000039.md) | [29.1%](/filings/0001295947-26-000008.md) | [26.8% d](/filings/0001295947-26-000016.md) | [19.8%](/filings/0001295947-26-000042.md) |
| Net margin | % | [19.2%](/filings/0001295947-25-000039.md) | [21.0%](/filings/0001295947-26-000008.md) | [16.9% d](/filings/0001295947-26-000016.md) | [19.0%](/filings/0001295947-26-000042.md) | [15.4%](/filings/0001295947-25-000039.md) | [16.5%](/filings/0001295947-26-000008.md) | [19.1% d](/filings/0001295947-26-000016.md) | [11.0%](/filings/0001295947-26-000042.md) |
| Diluted EPS | $ per share | [1.09](/filings/0001295947-25-000039.md) | [1.22](/filings/0001295947-26-000008.md) | not reported | [0.95](/filings/0001295947-26-000042.md) | [0.86](/filings/0001295947-25-000039.md) | [0.97](/filings/0001295947-26-000008.md) | not reported | [0.61](/filings/0001295947-26-000042.md) |
| Free cash flow | $m | [67.8 d](/filings/0001295947-25-000039.md) | [63.5 d](/filings/0001295947-26-000008.md) | [58.4 d](/filings/0001295947-26-000016.md) | [78.2](/filings/0001295947-26-000042.md) | [55.4 d](/filings/0001295947-25-000039.md) | [75.3 d](/filings/0001295947-26-000008.md) | [37.6 d](/filings/0001295947-26-000016.md) | [67.1](/filings/0001295947-26-000042.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,087](/filings/0001295947-24-000017.md) | [1,128](/filings/0001295947-25-000017.md) | [1,125](/filings/0001295947-26-000016.md) | [1,138](/filings/0001295947-26-000016.md) | [1,089](/filings/0001295947-26-000016.md) |
| Gross margin | % | [57.1%](/filings/0001295947-24-000017.md) | [55.4%](/filings/0001295947-25-000017.md) | [55.5%](/filings/0001295947-26-000016.md) | [55.8%](/filings/0001295947-26-000016.md) | [54.7%](/filings/0001295947-26-000016.md) |
| Operating margin | % | [30.4%](/filings/0001295947-24-000017.md) | [(2.0%)](/filings/0001295947-25-000017.md) | [30.4%](/filings/0001295947-26-000016.md) | [29.6%](/filings/0001295947-26-000016.md) | [28.4%](/filings/0001295947-26-000016.md) |
| Net margin | % | [18.9%](/filings/0001295947-24-000017.md) | [(7.3%)](/filings/0001295947-25-000017.md) | [18.6%](/filings/0001295947-26-000016.md) | [18.9%](/filings/0001295947-26-000016.md) | [17.5%](/filings/0001295947-26-000016.md) |
| Diluted EPS | $ per share | [4.04](/filings/0001295947-24-000017.md) | [(1.65)](/filings/0001295947-25-000017.md) | [4.17](/filings/0001295947-26-000016.md) | [4.29](/filings/0001295947-26-000016.md) | [3.91](/filings/0001295947-26-000016.md) |
| Free cash flow | $m | [250](/filings/0001295947-24-000017.md) | [222](/filings/0001295947-25-000017.md) | [239](/filings/0001295947-26-000016.md) | [243](/filings/0001295947-26-000016.md) | [246](/filings/0001295947-26-000016.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pbh/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $370.2m | 7,831,333 |  | Added +442,843 |
| [ARIEL INVESTMENTS, LLC](/funds/936753.md) | 2026-06-30 | $230.1m | 4,868,711 |  | Added +594,385 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $133.6m | 2,825,340 |  | Added +21,512 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $125.8m | 2,661,291 |  | Reduced −11,486 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $110.2m | 2,331,821 |  | New +2,331,821 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $101.0m | 2,136,944 |  | Added +43,951 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $100.0m | 2,116,513 |  | Added +145,532 |
| [BRANDES INVESTMENT PARTNERS, LP](/funds/1015079.md) | 2026-06-30 | $97.0m | 2,051,060 |  | Added +1,196,941 |
| [KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC](/funds/1021223.md) | 2026-06-30 | $88.5m | 1,872,023 |  | Reduced −330,583 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $74.3m | 1,571,742 |  | Added +111,707 |

## Recent filings

[All 985 filings](/companies/pbh/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-14 | 16:03 ET | [8-K](/filings/0001295947-26-000049.md) | 5.02 Departure or appointment of officers or directors | 0001295947-26-000049 |
| 2026-08-06 | 06:15 ET | [10-Q](/filings/0001295947-26-000042.md) | Quarterly report, period 2026-06-30 | 0001295947-26-000042 |
| 2026-08-06 | 06:04 ET | [8-K](/filings/0001295947-26-000040.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001295947-26-000040 |
| 2026-07-15 | 16:03 ET | [8-K](/filings/0001104659-26-083872.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-083872 |
| 2026-07-09 | 16:43 ET | [8-K/A](/filings/0001295947-26-000032.md) | 9.01 Financial statements and exhibits | 0001295947-26-000032 |
| 2026-07-06 | 08:05 ET | [8-K](/filings/0001295947-26-000029.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001295947-26-000029 |
| 2026-06-30 | 06:01 ET | [8-K/A](/filings/0001295947-26-000025.md) | 9.01 Financial statements and exhibits | 0001295947-26-000025 |
| 2026-06-29 | 06:06 ET | [DEF 14A](/filings/0001295947-26-000021.md) | Proxy statement, period 2026-06-29 | 0001295947-26-000021 |
| 2026-06-16 | 06:15 ET | [8-K](/filings/0001104659-26-074259.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-074259 |
| 2026-05-14 | 16:32 ET | [10-K](/filings/0001295947-26-000016.md) | Annual report, period 2026-03-31 | 0001295947-26-000016 |

## Latest annual report

[Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001295947-26-000016.md), filed May 14, 2026.

## Forecast league

Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/47d8619d-d48d-419f-9fb7-8e28a46e6b85)

## About the filer

- CIK: 1295947
- Tickers: PBH
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.